Advertisement

Vitiligo pp 25-37 | Cite as

Vitiligo: Histopathology, Including Electron Microscopy

  • Carlo CotaEmail author
  • Daniela Kovacs
Chapter

Abstract

The diagnosis of vitiligo is mainly based on clinical features; thus the role of the histological evaluation is generally poorly considered. However, the increasing interest in predicting the stability of the disease has reawakened awareness of the histopathological features of vitiligo. Histopathologically, both epidermal and dermal changes characterize vitiligo, mainly in relation to the activity and duration of the disease. Microscopical alterations of vitiligo may be subtle and overlooked in routine practice; thus a clinico-pathological correlation is crucial for a proper diagnosis.

References

  1. 1.
    Montes LF, Abulafia J, Wilborn WH, et al. Value of histopathology in vitiligo. Int J Dermatol. 2003;42(1):57–61.PubMedCrossRefGoogle Scholar
  2. 2.
    Yadav AK, Singh P, Khunger N. Clinicopathologic analysis of stable and unstable vitiligo: a study of 66 cases. Am J Dermatopathol. 2016;38(8):608–13.  https://doi.org/10.1097/DAD.0000000000000539.PubMedCrossRefGoogle Scholar
  3. 3.
    Bolognia JL, Jorizzo JL, Schaffer JV. Dermatology. 3rd ed. London: Elsevier; 2012.Google Scholar
  4. 4.
    Tobin DJ, Swanson NN, Pittelkow MR, et al. Melanocytes are not absent in lesional skin of long duration vitiligo. J Pathol. 2000;191:407–16.PubMedCrossRefGoogle Scholar
  5. 5.
    Anbar TS, El-Sawy AE, Attia SK, et al. Effect of PUVA therapy on melanocytes and keratinocytes in non-segmental vitiligo: histopathological, immuno-histochemical and ultrastructural study. Photodermatol Photoimmunol Photomed. 2012;28(1):17–25.  https://doi.org/10.1111/j.1600-0781.2011.00631.x.PubMedCrossRefGoogle Scholar
  6. 6.
    Kubanov A, Proshutinskaia D, Volnukhin V, et al. Immunohistochemical analysis of melanocyte content in different zones of vitiligo lesions using the Melan-A marker. Acta Dermatovenerol Alp Pannonica Adriat. 2016;25(1):5–9.PubMedGoogle Scholar
  7. 7.
    Kim YC, Kim YJ, Kang HY, et al. Histopathologic features in vitiligo. Am J Dermatopathol. 2008;30(2):112–6.  https://doi.org/10.1097/DAD.0b013e3181651511.PubMedCrossRefGoogle Scholar
  8. 8.
    Gan EY, Cario-André M, Pain C, et al. Follicular vitiligo: a report of 8 cases. J Am Acad Dermatol. 2016;74:1178–84.PubMedCrossRefGoogle Scholar
  9. 9.
    van den Wijngaard R, Wankowicz-Kalinska A, Le Poole C, et al. Local immune response in skin of generalized vitiligo patients. Destruction of melanocytes is associated with the prominent presence of CLA+ T cells at the perilesional site. Lab Invest. 2000;80(8):1299–309.PubMedCrossRefGoogle Scholar
  10. 10.
    Weedon D. Weedon’s skin pathology. 3rd ed. London: Elsevier; 2010.Google Scholar
  11. 11.
    Abdel-Naser MB, Krüger-Krasagakes S, Krasagakis K, et al. Further evidence for involvement of both cell mediated and humoral immunity in generalized vitiligo. Pigment Cell Res. 1994;7(1):1–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Attili VR, Attili SK. Lichenoid inflammation in vitiligo – a clinical and histopathologic review of 210 cases. Int J Dermatol. 2008;47:663–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Sharquie KE, Mehenna SH, Naji AA, et al. Inflammatory changes in vitiligo: stage I and II depigmentation. Am J Dermatopathol. 2004;26(2):108–12.PubMedCrossRefGoogle Scholar
  14. 14.
    Moellmann G, Klein-Angerer S, Scollay DA, et al. Extracellular granular material and degeneration of keratinocytes in the normally pigmented epidermis of patients with vitiligo. J Invest Dermatol. 1982;79(5):321–30.PubMedCrossRefGoogle Scholar
  15. 15.
    El-Darouti MA, Marzouk SA, Azzam O, et al. Vitiligo vs. hypopigmented mycosis fungoides (histopathological and immunohistochemical study, univariate analysis). Eur J Dermatol. 2006;16(1):17–22.PubMedGoogle Scholar
  16. 16.
    Stylianos V, Eleftherios I, Nikolaos K, et al. Correlating epidermal thickness and basement membrane length to angiogenesis in the centre and the periphery of vitiligo lesion. Indian J Dermatol Venereol Leprol. 2012;78(3):368–71.  https://doi.org/10.4103/0378-6323.95462.PubMedCrossRefGoogle Scholar
  17. 17.
    Jung SE, Kang HY, Lee ES, et al. Changes of epidermal thickness in vitiligo. Am J Dermatopathol. 2015;37(4):289–92.PubMedCrossRefGoogle Scholar
  18. 18.
    Kao CH, Yu HS. Depletion and repopulation of Langerhans cells in nonsegmental type vitiligo. J Dermatol. 1990;17(5):287–96.PubMedCrossRefGoogle Scholar
  19. 19.
    Brown J, Winklemann RK, Wolff K. Langerhans cells in vitiligo: a qualitative study. J Invest Dermatol. 1967;49(4):386–90.PubMedCrossRefGoogle Scholar
  20. 20.
    Claudy AL, Rouchouse B. Langerhans’ cell and vitiligo: quantitative study of T6 and HLA-DR antigen-expressing cells. Acta Derm Venereol. 1984;64(4):334–6.PubMedGoogle Scholar
  21. 21.
    Meheregan AH, Hashimoto K. Pinkus’ guide to dermatopathology. Norwalk, CT: Appleton & Lange; 1991.Google Scholar
  22. 22.
    Gokhale BB, Mehta LN. Histopathology of vitiliginous skin. Int J Dermatol. 1983;22(8):477–80.PubMedCrossRefGoogle Scholar
  23. 23.
    Benzekri L, Gauthier Y, Hamada S, et al. Clinical features and histological findings are potential indicators of activity in lesions of common vitiligo. Br J Dermatol. 2013;168(2):265–71.  https://doi.org/10.1111/bjd.12034.PubMedCrossRefGoogle Scholar
  24. 24.
    Kovacs D, Abdel-Raouf H, Al-Khayyat M, et al. Vitiligo: characterized of melanocytes in repigmented skin after punch grafting. J Eur Acad Dermatol Venereol. 2015;29:581–90.  https://doi.org/10.1111/jdv.12647.PubMedCrossRefGoogle Scholar
  25. 25.
    Le Poole IC, van den Wijngaard RM, Westerhof W, et al. Presence or absence of melanocytes in vitiligo lesions: an immunohistochemical investigation. J Invest Dermatol. 1993;100(6):816–22.PubMedCrossRefGoogle Scholar
  26. 26.
    Wańkowicz-Kalińska A, van den Wijngaard RM, Tigges BJ, et al. Immunopolarization of CD4+ and CD8+ T cells to Type-1-like is associated with melanocyte loss in human vitiligo. Lab Invest. 2003;83(5):683–95.PubMedCrossRefGoogle Scholar
  27. 27.
    Pretti Aslanian FM, Noé RA, Cuzzi T, et al. Abnormal histological findings in active vitiligo include the normal-appearing skin. Pigment Cell Res. 2007;20(2):144–5.PubMedCrossRefGoogle Scholar
  28. 28.
    Gauthier Y, Cario Andre M, Taïeb A. A critical appraisal of vitiligo etiologic theories. Is melanocyte loss a melanocytorrhagy? Pigment Cell Res. 2003;16:322–32.PubMedCrossRefGoogle Scholar
  29. 29.
    Norris A, Todd C, Graham A, et al. The expression of the c-kit receptor by epidermal melanocytes may be reduced in vitiligo. Br J Dermatol. 1996;134(2):299–306.PubMedCrossRefGoogle Scholar
  30. 30.
    Wagner RY, Luciani F, Cario-André M, et al. Altered E-cadherin levels and distribution in melanocytes precede clinical manifestations of vitiligo. J Invest Dermatol. 2015;135(7):1810–9.  https://doi.org/10.1038/jid.2015.25.PubMedCrossRefGoogle Scholar
  31. 31.
    Al Badri AMT, Tood PM, Garioch JJ, et al. An immunohistochemical study of cutaneous lymphocytes in vitiligo. J Pathol. 1993;170:149–55.PubMedCrossRefGoogle Scholar
  32. 32.
    Ahn SK, Choi EH, Lee SH, et al. Immunohistochemical studies from vitiligo – comparison between active and inactive lesions. Yonsei Med J. 1994;35:404–10.PubMedCrossRefGoogle Scholar
  33. 33.
    Le Poole IC, Van den Wijngaard RM, Westerhof W, et al. Presence of T-cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance. Am J Pathol. 1996;148:1219–28.PubMedPubMedCentralGoogle Scholar
  34. 34.
    Pretti Aslanian FM, Noè RAM, Antelo DP, et al. Immunohistochemical findings in active vitiligo including depigmenting lesions and non-lesional skin. Open Dermatol J. 2008;2:105–10.CrossRefGoogle Scholar
  35. 35.
    Breathnach AS, Bor S, Wyllie LM. Electron microscopy of peripheral nerve terminals and marginal melanocytes in vitiligo. J Invest Dermatol. 1966;47(2):125–40.PubMedCrossRefGoogle Scholar
  36. 36.
    Galadari E, Mehregan AH, Hashimoto K. Ultrastructural study of vitiligo. Int J Dermatol. 1983;32(4):269–71.CrossRefGoogle Scholar
  37. 37.
    Prignano F, Pescitelli L, Becatti M, et al. Ultrastructural and functional alterations of mitochondria in perilesional vitiligo skin. J Dermatol Sci. 2009;54(3):157–67.  https://doi.org/10.1016/j.jdermsci.2009.02.004.PubMedCrossRefGoogle Scholar
  38. 38.
    Prignano F, Ricceri F, Bianchi B, et al. Dendritic cells: ultrastructural and immunophenotypical changes upon nb-UVB in vitiligo skin. Arch Dermatol Res. 2011;303(4):231–8.  https://doi.org/10.1007/s00403-010-1109-5.PubMedCrossRefGoogle Scholar
  39. 39.
    Fawzy MM, El Maadawi ZM, Hegazy RA, et al. Vitiligo - the story from within: a transmission electron microscopic study before and after narrow-band ultraviolet B. Ultrastruct Pathol. 2016;40(5):265–75.  https://doi.org/10.1080/01913123.2016.1218987.PubMedCrossRefGoogle Scholar
  40. 40.
    Hann SK, Park YK, Lee KG, et al. Epidermal changes in active vitiligo. J Dermatol. 1992;19(4):217–22.PubMedCrossRefGoogle Scholar
  41. 41.
    Ding GZ, Zhao WE, Li X, et al. A comparative study of mitochondrial ultrastructure in melanocytes from perilesional vitiligo skin and perilesional halo nevi skin. Arch Dermatol Res. 2015;307(3):281–9.  https://doi.org/10.1007/s00403-015-1544-4.PubMedCrossRefGoogle Scholar
  42. 42.
    Panuncio AL, Vignale R. Ultrastructural studies in stable vitiligo. Am J Dermatopathol. 2003;25(1):16–20.PubMedCrossRefGoogle Scholar
  43. 43.
    Bartosik J, Wulf HC, Kobayasi T. Melanin and melanosome complexes in long standing stable vitiligo—an ultrastructural study. Eur J Dermatol. 1998;8(2):95–7.PubMedGoogle Scholar
  44. 44.
    Al’Abadie MS, Warren MA, Bleehen SS, et al. Morphologic observations on the dermal nerves in vitiligo: an ultrastructural study. Int J Dermatol. 1995;34(12):837–40.PubMedCrossRefGoogle Scholar
  45. 45.
    Iannella G, Greco A, Didona D, et al. Vitiligo: pathogenesis, clinical variants and treatment approaches. Autoimmun Rev. 2016;15:335–43.PubMedCrossRefGoogle Scholar
  46. 46.
    Kim SK, Kang HY, Lee ES, et al. Clinical and histopathologic characteristics of nevus depigmentosus. J Am Acad Dermatol. 2006;55:423–8.PubMedCrossRefGoogle Scholar
  47. 47.
    Dean NR, Brennan J, Haynes J, et al. Immunohistochemical labeling of normal melanocytes. Appl Immunohistochem Mol Morphol. 2002;10(3):199–204.PubMedGoogle Scholar
  48. 48.
    King R, Weilbaecher KN, McGill G, et al. Microphthalmia transcription factor. A sensitive and specific melanocyte marker for Melanoma Diagnosis. Am J Pathol. 1999;155(3):731–8.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Prieto VG, Shea CR. Immunohistochemistry of melanocytic proliferations. Arch Pathol Lab Med. 2011;135(7):853–9.  https://doi.org/10.1043/2009-0717-RAR.1.PubMedCrossRefGoogle Scholar
  50. 50.
    Passeron T, Coelho SG, Miyamura Y, et al. Immunohistochemistry and in situ hybridization in the study of human skin melanocytes. Exp Dermatol. 2007;16(3):162–70.PubMedCrossRefGoogle Scholar
  51. 51.
    Clarkson KS, Sturdgess IC, Molyneux AJ. The usefulness of tyrosinase in the immunohistochemical assessment of melanocytic lesions: a comparison of the novel T311 antibody (anti-tyrosinase) with S-100, HMB45, and A103 (anti-melan-A). J Clin Pathol. 2001;54(3):196–200.PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Kawakami Y, Eliyahu S, Delgado CH, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A. 1994;91(9):3515–9.PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Coulie PG, Brichard V, Van Pel A, et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med. 1994;180(1):35–42.PubMedCrossRefGoogle Scholar
  54. 54.
    Grabbe J, Welker P, Dippel E, et al. Stem cell factor, a novel cutaneous growth factor for mast cells and melanocytes. Arch Dermatol Res. 1994;287(1):78–84.PubMedCrossRefGoogle Scholar
  55. 55.
    Steel KP, Davidson DR, Jackson IJ. TRP-2/DT, a new early melanoblast marker, shows that steel growth factor (c-kit ligand) is a survival factor. Development. 1992;115(4):1111–9.PubMedGoogle Scholar
  56. 56.
    Gown AM, Vogel AM, Hoak D, et al. Monoclonal antibodies specific for melanocytic tumors distinguish subpopulations of melanocytes. Am J Pathol. 1986;123(2):195–203.PubMedPubMedCentralGoogle Scholar
  57. 57.
    Smoller BR, Hsu A, Krueger J. HMB-45 monoclonal antibody recognizes an inducible and reversible melanocyte cytoplasmic protein. J Cutan Pathol. 1991;18(5):315–22.PubMedCrossRefGoogle Scholar
  58. 58.
    Vennegoor C, Hageman P, Van Nouhuijs H, et al. A monoclonal antibody specific for cells of the melanocyte lineage. Am J Pathol. 1988;130(1):179–92.PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Dermatopathology UnitSan Gallicano Dermatologic Institute (IRCCS)RomeItaly
  2. 2.Laboratory of Cutaneous Physiopathology and Integrated Center of Metabolomics ResearchSan Gallicano Dermatologic Institute (IRCCS)RomeItaly

Personalised recommendations